<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11458">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732406</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001556</org_study_id>
    <nct_id>NCT01732406</nct_id>
  </id_info>
  <brief_title>Acromegaly Treatment Quality of Life Study</brief_title>
  <official_title>Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that treatment of acromegaly will be associated with an
      improvement in quality of life compared to active acromegaly. At the same time, they will
      also be studying the effects of different acromegaly treatments on the quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Acomegaly with Pegvisomant</arm_group_label>
    <description>Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acromegaly with somatostatin analog</arm_group_label>
    <description>Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Acromegaly</arm_group_label>
    <description>Patients not on drugs for treatment of acromegaly</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and blood serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There will be 3 groups/cohorts: 1) Patients with active acromegaly (n=30), 2) patients
        receiving pegvisomant monotherapy to treat acromegaly (n=30), and 3) patients receiving
        somatostatin analog monotherapy to treat acromegaly (n=60)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75

          -  Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin
             analog monotherapy

        Exclusion Criteria:

          -  Untreated thyroid or adrenal insufficiency.  Subjects on replacement therapy must be
             stable for at least 3 months prior to entry into the study

          -  Initiation or discontinuation of testosterone or estrogen within 3 months of entry

          -  Pregnant and nursing women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu v Gerweck, NP</last_name>
    <phone>617-724-1837</phone>
    <email>avgerweck@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu V Gerweck, NP</last_name>
      <phone>617-724-1837</phone>
      <email>avgerweck@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Assistant Physician in Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
